Imaging β-amyloid burden in aging and dementia

Neurology

Volumn 68, Issue 20, 2007, Pages 1718-1725

  Rowe, C C ^a,b   Ng, S ^a   Ackermann, U ^a   Gong, S J ^a   Pike, K ^c   Savage, G ^c   Cowie, T F ^b   Dickinson, K L ^a   Maruff, P ^d   Darby, D ^d   Smith, C ^a   Woodward, M ^b   Merory, J ^b   Tochon Danguy, H ^a   O'Keefe, G ^a   Klunk, W E ^f   Mathis, C A ^f   Price, J C ^f   Masters, C L ^b,e   Villemagne, V L ^a,b,e  

^a AUSTIN HEALTH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c MONASH UNIVERSITY   (Australia)

^d Cogstate Pty Ltd ^*  (Australia)

^e FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

^f UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; BENZOTHIAZOLE DERIVATIVE; BIOLOGICAL MARKER; CHOLINESTERASE INHIBITOR; PITTSBURGH COMPOUND B C 11; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ADULT; AGED; AGING; ALLELE; ALZHEIMER DISEASE; ARTICLE; BRAIN CORTEX; BRAIN REGION; CAUDATE NUCLEUS; CINGULATE GYRUS; COGNITIVE DEFECT; CONTROLLED STUDY; CORRELATION ANALYSIS; DEMENTIA; DIFFUSE LEWY BODY DISEASE; DISEASE COURSE; DISEASE SEVERITY; FEASIBILITY STUDY; FEMALE; FRONTAL CORTEX; FRONTOTEMPORAL DEMENTIA; HISTOPATHOLOGY; HUMAN; LIGAND BINDING; MAJOR CLINICAL STUDY; MALE; NERVE DEGENERATION; NEUROIMAGING; NEUROPSYCHOLOGICAL TEST; NON INVASIVE MEASUREMENT; PARIETAL LOBE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN LOCALIZATION; QUANTITATIVE ANALYSIS; TEMPORAL CORTEX; TISSUE DISTRIBUTION;

AGED; AGED, 80 AND OVER; AGING; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANILINE COMPOUNDS; APOLIPOPROTEINS E; BRAIN CHEMISTRY; CARBON RADIOISOTOPES; COGNITION DISORDERS; DEMENTIA; FEMALE; GYRUS CINGULI; HUMANS; LEWY BODY DISEASE; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOCORTEX; RADIOPHARMACEUTICALS; THIAZOLES;

EID: 34248579291     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000261919.22630.ea     Document Type: Article

References (50)

1. Wisniewski KE, Wisniewski HM, Wen GY. Occurrence of neuropathological changes and dementia of Alzheimer's disease in Down's syndrome. Ann Neurol 1985;17:278-282.
2. Price JL, Morris JC. Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease. Ann Neurol 1999;45:358-368.
3. Bennett DA, Schneider JA, Arvanitakis Z, et al. Neuropathology of older persons without cognitive impairment from two community-based studies. Neurology 2006;66:1837-1844.
4. McKeith IG, Galasko D, Kosaka K, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the Consortium on DLB International Workshop. Neurology 1996;47:1113-1124.
5. McKeith I, Mintzer J, Aarsland D, et al. Dementia with Lewy bodies. Lancet Neurol 2004;3:19-28.
6. McKeith IG, Dickson DW, Lowe J, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005;65:1863-1872.
7. Connor DJ, Salmon DP, Sandy TJ, et al. Cognitive profiles of autopsy-confirmed Lewy body variant vs pure Alzheimer disease. Arch Neurol 1998;55:994-1000.
8. Del Ser T, Hachinski V, Merskey H, Munoz DG. Clinical and pathologic features of two groups of patients with dementia with Lewy bodies: effect of coexisting Alzheimer-type lesion load. Alzheimer Dis 2001;15:31-44.
9. Merdes AR, Hansen LA, Jeste DV, et al. Influence of Alzheimer pathology on clinical diagnostic accuracy in dementia with Lewy bodies. Neurology 2003;60:1586-1590.
10. Ballard CG, Jacoby R, Del Ser T, et al. Neuropathological substrates of psychiatric symptoms in prospectively studied patients with autopsy-confirmed dementia with Lewy bodies. Am J Psychiatry 2004;161:843-849.
11. Harding AJ, Broe GA, Halliday GM. Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe. Brain 2002;125:391-403.
12. Jellinger KA. Influence of Alzheimer pathology on clinical diagnostic accuracy in dementia with Lewy bodies. Neurology 2004;62:160.
13. McKhann GM, Albert MS, Grossman M, et al. Clinical and pathological diagnosis of frontotemporal dementia: report of the Work Group on Frontotemporal Dementia and Pick's Disease. Arch Neurol 2001;58:1803-1809.
14. Mathis CA, Bacskai BJ, Kajdasz ST, et al. A lipophilic thioflavin-T derivative for positron emission tomography (PET) imaging of amyloid in brain. Bioorg Med Chem Lett 2002;12:295-298.
15. Klunk WE, Wang Y, Huang GF, et al. Uncharged thioflavin-T derivatives bind to amyloid-beta protein with high affinity and readily enter the brain. Life Sci 2001;69:1471-1484.
16. Klunk WE, Wang Y, Huang GF, et al. The binding of 2-(4′- methylaminophenyl)benzothiazole to postmortem brain homogenates is dominated by the amyloid component. J Neurosci 2003;23:2086-2092.
17. Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 2004;55:306-319.
18. Verhoeff NP, Wilson AA, Takeshita S, et al. In-vivo imaging of Alzheimer disease beta-amyloid with [11C]SB-13 PET. Am J Geriatr Psychiatry 2004;12:584-595.
19. Buckner RL, Snyder AZ, Shannon BJ, et al. Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory. J Neurosci 2005;25:7709-7717.
20. Price JC, Klunk WE, Lopresti BJ, et al. Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B. J Cereb Blood Flow Metab 2005;25:1528-1547.
21. Kemppainen NM, Aalto S, Wilson IA, et al. Voxel-based analysis of PET amyloid ligand [11C]PIB uptake in Alzheimer disease. Neurology 2006;67:1575-1580.
22. Archer HA, Edison P, Brooks DJ, et al. Amyloid load and cerebral atrophy in Alzheimer's disease: an 11C-PIB positron emission tomography study. Ann Neurol 2006;60:145-147.
23. Fagan AM, Mintun MA, Mach RH, et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta(42) in humans. Ann Neurol 2006;59:512-519.
24. 18F]FDG PET study. Neurology 2006.
25. Folstein MF, Folstein SE, McHugh PR."Mini-Mental State." A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
26. Morris JC.The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993;43:2412-2414.
27. McKhann G, Drachman D, Folstein M, et al. Clinical Diagnosis of Alzheimer's Disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-944.
28. Petersen RC, Smith GE, Waring SC, et al. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999;56:303-308.
29. Wilson AA, Garcia A, Chestakova A, Kung H, Houle S. A rapid one-step radiosynthesis of the β-amyloid imaging radiotracer N-methyl-[11C]2(40- methylaminophenyl)-6-hydroxybenzothiazole ([11C]-6-OH-BTA-1). J Label Compd Radiopharm 2004;47:679-682.
30. Friston KJ, Frith CD, Liddle PF, Frackowiak RS. Comparing functional (PET) images: the assessment of significant change. J Cereb Blood Flow Metab 1991;11:690-699.
31. Logan J, Fowler JS, Volkow ND, et al. Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab 1996;16:834-840.
32. Lopresti BJ, Klunk WE, Mathis CA, et al. Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis. J Nucl Med 2005;46:1959-1972.
33. Braak H, Braak E.Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging 1997;18:351-357.
34. Jorm AF, Jolley D.The incidence of dementia: a metaanalysis. Neurology 1998;51:728-733.
35. 11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology 2006;67:446-452.
36. Haroutunian V, Serby M, Purohit DP, et al. Contribution of Lewy body inclusions to dementia in patients with and without Alzheimer disease neuropathological conditions. Arch Neurol 2000;57:1145-1150.
37. Naslund J, Haroutunian V, Mohs R, et al. Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. JAMA 2000;283:1571-1577.
38. Parvathy S, Davies P, Haroutunian V, et al. Correlation between Abetax-40-, Abetax-42-, and Abetax-43-containing amyloid plaques and cognitive decline. Arch Neurol 2001;58:2025-2032.
39. Prohovnik I, Perl DP, Davis KL, et al. Dissociation of neuropathology from severity of dementia in late-onset Alzheimer disease. Neurology 2006;66:49-55.
40. McLean CA, Cherny RA, Fraser FW, et al. Soluble pool of Aβ amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol 1999;46:860-866.
41. Engler H, Forsberg A, Almkvist O, et al. Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. Brain 2006;129:2856-2866.
42. Meltzer CC, Zubieta JK, Brandt J, et al. Regional hypometabolism in Alzheimer's disease as measured by positron emission tomography after correction for effects of partial volume averaging. Neurology 1996;47:454-461.
43. Joachim CL, Morris JH, Selkoe DJ. Diffuse senile plaques occur commonly in the cerebellum in Alzheimer's disease. Am J Pathol 1989;135:309-319.
44. Yamaguchi H, Hirai S, Morimatsu M, Shoji M, Nakazato Y. Diffuse type of senile plaques in the cerebellum of Alzheimer-type dementia demonstrated by beta protein immunostain. Acta Neuropathol (Berl) 1989;77:314-319.
45. Thal DR, Rub U, Orantes M, Braak H. Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology 2002;58:1791-1800.
46. Brilliant MJ, Elble RJ, Ghobrial M, Struble RG. The distribution of amyloid beta protein deposition in the corpus striatum of patients with Alzheimer's disease. Neuropathol Appl Neurobiol 1997;23:322-325.
47. Rudelli RD, Ambler MW, Wisniewski HM. Morphology and distribution of Alzheimer neuritic (senile) and amyloid plaques in striatum and diencephalon. Acta Neuropathol (Berl) 1984;64:273-281.
48. Armstrong RA, Cairns NJ, Lantos PL. Beta-amyloid deposition in the temporal lobe of patients with dementia with Lewy bodies: comparison with non-demented cases and Alzheimer's disease. Dement Geriatr Cogn Disord 2000;11:187-192.
49. Pletnikova O, West N, Lee MK, et al. Abeta deposition is associated with enhanced cortical alpha-synuclein lesions in Lewy body diseases. Neurobiol Aging 2005;26:1183-1192.
50. Masliah E, Rockenstein E, Veinbergs I, et al. Beta-amyloid peptides enhance alpha-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease. Proc Natl Acad Sci USA 2001;98:12245-12250.